BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30458796)

  • 1. Combination of serum lipids and cancer antigens as a novel marker for colon cancer diagnosis.
    Li T; Qian Y; Li H; Deng J
    Lipids Health Dis; 2018 Nov; 17(1):261. PubMed ID: 30458796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of a diagnostic score for colon cancer based on serum CEA, CA19-9, cytokeratin-1 and mucin-1.
    Attallah AM; El-Far M; Ibrahim AR; El-Desouky MA; Omran MM; Elbendary MS; Attallah KA; Qura ER; Abdallah SO
    Br J Biomed Sci; 2018 Jul; 75(3):122-127. PubMed ID: 29734875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
    Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
    Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CEA and CA19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia.
    Zhai H; Huang J; Yang C; Fu Y; Yang B
    Clin Lab; 2018 Mar; 64(3):351-356. PubMed ID: 29739122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
    Yang XQ; Chen C; Wang FB; Peng CW; Li Y
    Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
    Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H
    BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in serum tumor markers between colon and rectal cancer. Comparison of CA 242 and carcinoembryonic antigen.
    Carpelan-Holmström MA; Haglund CH; Roberts PJ
    Dis Colon Rectum; 1996 Jul; 39(7):799-805. PubMed ID: 8674374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma.
    Vukobrat-Bijedic Z; Husic-Selimovic A; Sofic A; Bijedic N; Bjelogrlic I; Gogov B; Mehmedovic A
    Med Arch; 2013 Dec; 67(6):397-401. PubMed ID: 25568506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
    Chen L; Zhang Y; Chen M; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
    Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
    Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Levels of TRIM72 Are Lower among Patients with Colon Cancer: Identification of a Potential Diagnostic Marker.
    Chen Z; Yin X; Li K; Chen S; Li H; Li Y; Zhang Q; Wang H; Qiu Y
    Tohoku J Exp Med; 2018 May; 245(1):61-68. PubMed ID: 29806630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
    Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
    Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
    Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
    Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics.
    Mourtzikou A; Stamouli M; Kroupis C; Christodoulou S; Skondra M; Kastania A; Pectasides D; Athanasas G; Dimas C
    Clin Lab; 2012; 58(5-6):441-8. PubMed ID: 22783573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA19-9 Concentration After First-line Chemotherapy Is Prognostic Predictor of Metastatic Colon Cancer.
    Hashizume R; Kawahara H; Ogawa M; Suwa K; Eto K; Yanaga K
    In Vivo; 2019; 33(6):2087-2093. PubMed ID: 31662542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
    Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
    Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer.
    Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Toyokawa T; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
    Anticancer Res; 2014 Jul; 34(7):3753-8. PubMed ID: 24982398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.